Cholesterol Control: How Does the ATGL Enzyme Affect It?

What did researchers discover about cholesterol control?

Researchers found that losing ACC1, an enzyme involved in fatty acid production, increased accessible membrane cholesterol approximately tenfold. Reducing fatty acyl-CoA molecules activated ATGL, which helped reshape the surrounding membrane lipids.

The resulting membrane became more fluid, increasing cholesterol accessibility while disrupting its transport and activating the cholesterol regulator SREBP2. Blocking ATGL produced the opposite membrane effects. The experiments establish a biological mechanism; they do not demonstrate a treatment benefit in patients. [Nature Communications study](https://www.nature.com/articles/s41467-026-78470-4)

How is accessible cholesterol different from blood cholesterol?

Cholesterol helps maintain cell membranes, but its interactions with neighboring molecules determine how readily it can engage with proteins. Earlier experiments identified three operational pools of membrane cholesterol: an accessible pool, a pool held by sphingomyelin, and a residual pool. These are different molecular environments for cholesterol, rather than three separate forms of the substance. [Foundational eLife study](https://elifesciences.org/articles/02882)

This organization helps explain how cells monitor their cholesterol supply. Cholesterol reaching an internal compartment called the endoplasmic reticulum influences SREBP signaling, which controls genes involved in cholesterol production and uptake. The implication is that cholesterol location and availability matter alongside its abundance: a cell must coordinate its outer membrane with the compartment that senses whether more cholesterol is needed. [eLife research](https://elifesciences.org/articles/02882)

What does cellular cholesterol research mean for patient care?

For patients, the established concern is that excessive LDL cholesterol contributes to plaque buildup in arteries. A routine lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. It does not measure the accessible cholesterol pool within cell membranes. These measurements answer different questions, so a laboratory change in membrane accessibility cannot be translated directly into a change in cardiovascular risk. [NHLBI cholesterol overview](https://www.nhlbi.nih.gov/health/blood-cholesterol), [NHLBI lipid testing](https://www.nhlbi.nih.gov/health/blood-cholesterol/diagnosis)

Established treatment combines appropriate lifestyle measures with medication when indicated. Statins reduce cholesterol production in the liver and help lower circulating LDL; other medicines work through different pathways. Before a cellular mechanism can support a new treatment, researchers need evidence about safety, effects across tissues and meaningful health outcomes. Decisions about existing cholesterol medication should therefore remain grounded in an individual's cardiovascular risk and clinical response. [NHLBI treatment guidance](https://www.nhlbi.nih.gov/health/blood-cholesterol/treatment)